Your browser doesn't support javascript.
loading
SARS-CoV-2 specific antibody responses in COVID-19 patients
NISREEN M.A. OKBA; Marcel A Muller; Wentao Li; Chunyan Wang; Corine H. GeurtsvanKessel; Victor M. Corman; Mart M. Lamers; Reina S. Sikkema; Erwin de Bruin; Felicity D. Chandler; Yazdan Yazdanpanah; Quentin Le Hingrat; Diane Descamps; Nadhira Houhou-Fidouh; Chantal B. E. M. Reusken; Berend-Jan Bosch; Christian Drosten; Marion P.G. Koopmans; Bart L. Haagmans.
Affiliation
  • NISREEN M.A. OKBA; Erasmus Medical Center
  • Marcel A Muller; Charite Universitatsmedizin
  • Wentao Li; Utrecht University
  • Chunyan Wang; Utrecht University
  • Corine H. GeurtsvanKessel; Erasmus Medical Center
  • Victor M. Corman; Charite Universitatsmedizin
  • Mart M. Lamers; Erasmus Medical Center
  • Reina S. Sikkema; Erasmus Medical Center
  • Erwin de Bruin; Erasmus Medical Center
  • Felicity D. Chandler; Erasmus Medical Center
  • Yazdan Yazdanpanah; Universite de Paris
  • Quentin Le Hingrat; Universite de Paris
  • Diane Descamps; Universite de Paris
  • Nadhira Houhou-Fidouh; Hopital Bichat-Claude Bernard
  • Chantal B. E. M. Reusken; Erasmus Medical Center
  • Berend-Jan Bosch; Utrecht University
  • Christian Drosten; Charite-Universitatsmedizin
  • Marion P.G. Koopmans; Erasmus Medical Center
  • Bart L. Haagmans; Erasmus Medical Center
Preprint in En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20038059
ABSTRACT
A new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic. Whereas molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies. Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrate that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs. We found that commercial S1 IgG or IgA ELISAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity. Overall, the validated assays described here can be instrumental for the detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiological and vaccine evaluation studies.
License
cc_no
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Diagnostic_studies / Experimental_studies / Observational_studies / Prognostic_studies Language: En Year: 2020 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Diagnostic_studies / Experimental_studies / Observational_studies / Prognostic_studies Language: En Year: 2020 Document type: Preprint